CD20scFv-IgGFc T 淋巴细胞的建立及其对B细胞淋巴瘤靶向杀伤作用的比较

目的：研究CD20scFv嵌合T淋巴细胞靶向杀伤Daudi细胞时杀伤的效果和T细胞活化情况。方法：将两种质粒转染至PA317细胞中，用转染成功的PA317上清液感染外周血T淋巴细胞后经800 mg/L的G418筛选1周后去杀伤Daudi、K562细胞，分别在不同时点用流式细胞仪检测Daudi细胞AnnexinⅤ的阳性率 ，用ELISA检测细胞因子IL-2、IFNγ。结果：Daudi细胞AnnexinⅤ的阳性率在24 h内两实验组与K562组相比明显增高，而实验组之间没有显著差异。72 h时CD20scFv-IgGFc-CD28-ζ组比CD20scFv-IgGFc组IL-2（1 509.00 ng/L比220.54 ng/L）和IFNγ（912.16 ng/L比251.42 ng/L）的分泌量有显著增高。结论：①两种CD20scFv特异的T细胞在引起Daudi细胞早期凋亡无显著差异，说明在CD20scFv的靶向杀伤过程中CD28-ζ基因可能不主导Daudi细胞的早期凋亡。②CD20scFv-IgGFc-CD28-ζ组IL-2、IFNγ增幅更加明显，说明CD3ζ和CD28嵌合的T细胞可以自身活化而不受MHC的限制，从而增强了T细胞的活化和杀伤等功能。

Establishment of T-lymphocytes that express CD20scFv-IgGFc-CD28-ζ and CD20scFv-IgGFc and their killing activity of B-lymphoma cells

AIM: To investigate the target killing effect of T lymphocytes with chimeric CD20scFv gene on Daudi cells and the activation of T lymphocytes. METHODS: Two kinds of plasmids were transfected into retrovirus-packed PA317 cell lines. The supernatant was collected from successfully transfected PA317 culture and was used to infect peripheral blood T lymphocytes. After one-week screening with G418, the cells were used to kill Daudi and K562 cells. The positive rates of AnnexinⅤ in Daudi cells were measured at different times points respectively by flow cytometry. Meanwhile, the level of IL-2 and IFN-γ were determined by ELISA. RESULTS: The Annexin V positive rate was significant higher in Daudi cells compared to control K562 cell lines at 24 h. No difference of AnnexinV in Daudi cells was observed in CD20 modification T lymphocyte groups. The secretions of IL-2 and IFN-γ in CD20scFv-CD80-IgGFc-CD28-ζ gene modified T cells co-cultured with Daudi cells were dramatically higher than that in CD20scFv-IgGFc group at 72 h. CONCLUSION: ① The two kinds of genetic modified specific T cells have no significant difference in inducing early apoptosis of Daudi cells. CD28-ζ cant affect Daudi cell early apoptosis at the CD20scFv target killing. ② The increase in the secretions of IL-2 and IFN-γ is more obvious in CD20scFv-IgGFc-CD28-ζ group, indicating that the self-activation takes place in CD3ζ and CD28 modified T cells without MHC restriction and then increases the activation and killing function of T cells.